The partnership between the Department of Veterans Affairs (VA) and the Institute for Clinical and Economic Review (ICER) has provided benefits across a number of fronts, according to a Health Affairs blog post by representatives of the agency and drug pricing watchdog.
Despite concerns that the partnership would hamper access to medications, that “has not been realized,” the authors write.
“Overall, the VA-ICER collaboration has been highly beneficial to VA on several fronts, most notably to help VA better understand the relative value of new drugs and in providing more concrete pricing benchmarks for medications that are often extremely costly upon release,” they write.
To read the full blog post, click here.
